KB113 Wipes Out Basal Cell Tumors in Gorlin Syndrome Pilot, Including Non-Injected Lesions
KRYS sits 85% above its 52-week low of $181.437.
Summary
Krystal's KB113, an intratumoral HSV-1 therapy expressing IL-2 and IL-12, produced regression in 83.1% of 83 assessed basal cell carcinoma lesions across three Gorlin syndrome patients, with 50.6% shrinking more than 50% and 9.6% shrinking at least 90%. Critically, responses appeared in lesions that were never injected — 85.1% of non-injected lesions regressed — evidence of a systemic abscopal effect, and biopsies of three injected lesions showed histologically confirmed complete clearance. All adverse events were mild to moderate and transient. This is early-stage data in just three patients, so it is proof of concept rather than a registrational readout, but it opens a second pipeline program beyond the commercial VYJUVEK franchise and comes with a market of roughly 10,000 US Gorlin patients who currently face repeated surgeries. The company has started FDA discussions on advanced development and says it will update on clinical plans after alignment with the agency.
At the time of this announcement, KRYS was trading at $335.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $181.44 to $382.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.